It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...

Oregon State inside linebacker Isaiah Chisom announced Tuesday that he’s transferring to UCLA. Chisom is the fourth Beaver from the 2024 roster to complete a transfer, and second headed to UCLA ...

Pyxis Oncology, Inc. is reallocating its resources to focus on the development of its leading asset, PYX-201, a pioneering antibody-drug conjugate (ADC) showing promising efficacy in treating head ...

Oregon has a Democratic trifecta and a Democratic triplex. The Democratic Party controls the offices of governor, secretary of state, attorney general, and both chambers of the state legislature. As ...

Pyxis Oncology said Thursday it will focus resources on its lead asset, PYX-201, which is being studied as a treatment for certain patients with head and neck squamous cell carcinoma, with ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Swayampakula Ramakanth’s rating is based on Pyxis Oncology’s strategic decision to prioritize PYX-201 ...

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

While investors can buy Dogecoin, there’s also another way to get DOGE: by mining it. Dogecoin mining works in much the same way as Bitcoin mining, but it doesn’t necessarily require expensive mining ...

In November 2024, Pyxis Oncology reported positive preliminary data from the ongoing Phase 1 dose-escalation study of PYX-201, evaluating its safety and efficacy in multiple solid tumor types.

The Company will focus resources on advancing its lead asset, PYX-201 - PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where significant RECIST responses were seen in head and ...